In addition to therapies directly affecting stromal cells, future efforts could be spent on developing NP-based therapies capable of tuning tumor-cell intrinsic pathways such as mTOR, p53, or STAT3 in cancer cells for the indirect modulation of the tumor immune microenvironment. The gene discussed is MTOR; the disease is neoplasm.